Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

WAVE Life Sciences stock

WVE
SG9999014716
A1436W

Price

15.40
Today +/-
+0.25
Today %
+1.75 %

WAVE Life Sciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the WAVE Life Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the WAVE Life Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the WAVE Life Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze WAVE Life Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

WAVE Life Sciences Stock Price History

DateWAVE Life Sciences Price
12/2/202415.40 undefined
11/29/202415.13 undefined
11/27/202414.99 undefined
11/26/202414.83 undefined
11/25/202414.89 undefined
11/22/202414.27 undefined
11/21/202414.35 undefined
11/20/202414.26 undefined
11/19/202414.21 undefined
11/18/202412.85 undefined
11/15/202413.67 undefined
11/14/202415.00 undefined
11/13/202416.29 undefined
11/12/202415.89 undefined
11/11/202416.44 undefined
11/8/202416.44 undefined
11/7/202414.83 undefined
11/6/202414.20 undefined
11/5/202413.84 undefined
11/4/202413.79 undefined

WAVE Life Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into WAVE Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by WAVE Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects WAVE Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of WAVE Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into WAVE Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing WAVE Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on WAVE Life Sciences’s growth potential.

WAVE Life Sciences Revenue, EBIT and net profit per share

DateWAVE Life Sciences RevenueWAVE Life Sciences EBITWAVE Life Sciences Net Income
2029e519.25 M undefined172.71 M undefined154.66 M undefined
2028e323.49 M undefined30.95 M undefined32.66 M undefined
2027e210.15 M undefined-41.58 M undefined-29.27 M undefined
2026e107.13 M undefined-135.02 M undefined-153.02 M undefined
2025e69.68 M undefined-159.53 M undefined-162.6 M undefined
2024e58.55 M undefined-164.42 M undefined-177.15 M undefined
2023113.31 M undefined-68 M undefined-57.51 M undefined
20223.65 M undefined-162.72 M undefined-161.82 M undefined
202140.96 M undefined-127.02 M undefined-122.25 M undefined
202020.08 M undefined-153.38 M undefined-149.91 M undefined
201915.98 M undefined-208.32 M undefined-193.64 M undefined
201814.41 M undefined-159.52 M undefined-146.65 M undefined
20173.89 M undefined-102.39 M undefined-101.98 M undefined
20161.09 M undefined-55.72 M undefined-55.66 M undefined
2015150,000 undefined-19.3 M undefined-19.2 M undefined
20140 undefined-5.39 M undefined-5.23 M undefined
20130 undefined-3.57 M undefined-3.32 M undefined

WAVE Life Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000131415204031135869107210323519
----200.00366.677.1433.33100.00-92.503,666.67-48.6718.9755.0796.2653.8160.68
-----------------
00000000000000000
-3-5-19-55-101-146-193-149-122-161-57-177-162-153-2932154
-66.67280.00189.4783.6444.5532.19-22.80-18.1231.97-64.60210.53-8.47-5.56-81.05-210.34381.25
20.9320.9310.522.826.5128.9733.8739.2351.8378.86106.1000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The WAVE Life Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the WAVE Life Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20132014201520162017201820192020202120222023
                     
0.41161.2150.3142.5174.8147.2184.5150.688.5200.35
0.10.20011020300021.09
00000000000
00000000000
0.30.20.11.7717.518.315.5121013.94
0.81.4161.3152150.5202.3185.5230162.698.5235.37
1.41.32.88.627.339.954.545.440.644.135.72
00000000000
0000050300000
00000000000
00000000000
0.20.21.34.243.714.33.83.83.73.86
1.61.54.112.831.393.698.849.244.447.839.58
2.42.9165.4164.8181.8295.9284.3279.2207146.3274.95
                     
2.617.9193.2223.5317.9383547.4702757.8810.7943.24
003.21022.237.857.371.688119.4129.24
-10.6-15.9-35.1-90.5-192.7-339.7-533.4-683.3-805.5-967.3-1,024.85
2001000-3001002003004002000-124
00000000000
-7.82.1161.3142.7147.581.371.690.740.5-37.247.5
0.20.12.84.97.613.19.113.87.316.912.84
0.20.40.63.58.91319.415.719.82323.54
0.10.30.43.71.7103.989.791.637.131.6150.06
9.60000000000
001001000000000
10.10.83.912.218.2130118.2121.164.271.5186.44
0010000000000
00000000000
000.29.916.284.794.567.5102.4112.141.01
000.39.916.284.794.567.5102.4112.141.01
10.10.84.222.134.4214.7212.7188.6166.6183.6227.45
2.32.9165.5164.8181.9296284.3279.3207.1146.4274.95
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of WAVE Life Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand WAVE Life Sciences's financial health and stability.

Assets

WAVE Life Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that WAVE Life Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of WAVE Life Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into WAVE Life Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
-3-5-19-55-101-146-193-149-122-161-57
00002578765
00000000000
001160102-2397619
0081427314030353723
00000000000
00000000000
-3-4-12-31-83-22-188-115-88-127-19
00-1-5-18-9-3-10-1-1
00-2-5-18-9-3-10-1-1
00-100000000
00000000000
30000000000
051753094651641545566131
351752994651641545567132
----1.00-------
00000000000
00160-8-732-2737-33-62111
-3.6-5.02-14.39-37.5-102.56-32.8-192.15-117.32-89.55-129.14-20.55
00000000000

WAVE Life Sciences stock margins

The WAVE Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of WAVE Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for WAVE Life Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the WAVE Life Sciences's sales revenue. A higher gross margin percentage indicates that the WAVE Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the WAVE Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the WAVE Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the WAVE Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the WAVE Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the WAVE Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

WAVE Life Sciences Margin History

WAVE Life Sciences Gross marginWAVE Life Sciences Profit marginWAVE Life Sciences EBIT marginWAVE Life Sciences Profit margin
2029e0 %33.26 %29.79 %
2028e0 %9.57 %10.1 %
2027e0 %-19.79 %-13.93 %
2026e0 %-126.03 %-142.83 %
2025e0 %-228.94 %-233.35 %
2024e0 %-280.82 %-302.58 %
20230 %-60.01 %-50.76 %
20220 %-4,458.08 %-4,433.42 %
20210 %-310.11 %-298.46 %
20200 %-763.84 %-746.56 %
20190 %-1,303.63 %-1,211.76 %
20180 %-1,107.01 %-1,017.7 %
20170 %-2,632.13 %-2,621.59 %
20160 %-5,111.93 %-5,106.42 %
20150 %-12,866.67 %-12,800 %
20140 %0 %0 %
20130 %0 %0 %

WAVE Life Sciences Stock Sales Revenue, EBIT, Earnings per Share

The WAVE Life Sciences earnings per share therefore indicates how much revenue WAVE Life Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue WAVE Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates WAVE Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of WAVE Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating WAVE Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

WAVE Life Sciences Revenue, EBIT and net profit per share

DateWAVE Life Sciences Sales per ShareWAVE Life Sciences EBIT per shareWAVE Life Sciences Earnings per Share
2029e3.4 undefined0 undefined1.01 undefined
2028e2.12 undefined0 undefined0.21 undefined
2027e1.38 undefined0 undefined-0.19 undefined
2026e0.7 undefined0 undefined-1 undefined
2025e0.46 undefined0 undefined-1.07 undefined
2024e0.38 undefined0 undefined-1.16 undefined
20231.07 undefined-0.64 undefined-0.54 undefined
20220.05 undefined-2.06 undefined-2.05 undefined
20210.79 undefined-2.45 undefined-2.36 undefined
20200.51 undefined-3.91 undefined-3.82 undefined
20190.47 undefined-6.15 undefined-5.72 undefined
20180.5 undefined-5.51 undefined-5.06 undefined
20170.15 undefined-3.86 undefined-3.85 undefined
20160.05 undefined-2.44 undefined-2.44 undefined
20150.01 undefined-1.84 undefined-1.83 undefined
20140 undefined-0.26 undefined-0.25 undefined
20130 undefined-0.17 undefined-0.16 undefined

WAVE Life Sciences business model

WAVE Life Sciences Ltd is a biotechnology company dedicated to the development of nucleic acid preparations for the treatment of genetically inherited diseases. The company was founded in 2012 and is headquartered in Singapore. WAVE Life Sciences' business model is focused on developing specific nucleic acid sequences that can selectively silence or correct defective genes associated with various diseases. The company offers these sequences as therapeutics that enable personalized treatment for patients. The company utilizes a proprietary platform technology called "AVIENNA" to selectively silence or correct defective genes. "AVIENNA" aims to optimize the physical properties of nucleic acids to improve their effectiveness and duration of action. WAVE Life Sciences has three business areas: neurology, cardiovascular diseases, and metabolic diseases. In the neurology area, the company focuses on the development of therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and Huntington's disease. In the cardiovascular diseases area, the company is working on therapeutics for cardiovascular diseases such as heart attack, stroke, and atherosclerosis. In the metabolic diseases area, WAVE Life Sciences is focused on the development of therapeutics for rare metabolic diseases such as Crohn's disease and Pompe disease. The most well-known product in WAVE Life Sciences' pipeline is "WVE-120101", a therapeutic for the treatment of ALS. The drug has been developed to target mutations in the SOD1 gene that can lead to ALS. WVE-120101 is currently in clinical trials and has the potential to become the first approved medication for patients with ALS. WAVE Life Sciences also collaborates closely with other companies to exchange technologies and know-how. In 2018, the company entered into a strategic partnership with Takeda Pharmaceutical to jointly develop therapeutics for the treatment of gastrointestinal diseases. The partnership aims to leverage the strengths of both companies and accelerate the development of innovative therapeutics. Overall, WAVE Life Sciences has a promising portfolio of therapeutics that have the potential to improve the lives of patients with genetically inherited diseases. The company follows a systematic and scientifically-based strategy in drug development to ensure the effectiveness and safety of its products. With its innovative business model and dedicated research and development, WAVE Life Sciences is well positioned to achieve a leading position in the biotechnology industry in the future. WAVE Life Sciences is one of the most popular companies on Eulerpool.com.

WAVE Life Sciences SWOT Analysis

Strengths

  • Strong research and development capabilities, allowing for the development of innovative therapeutic products.
  • Technological expertise in RNA-based therapeutics.
  • Well-established partnerships and collaborations with leading pharmaceutical companies.

Weaknesses

  • Relatively small scale and limited resources compared to larger competitors, which may hinder market penetration.
  • Heavy reliance on a few key products, making the company vulnerable to market fluctuations.
  • Limited geographic presence, primarily focusing on specific regions, which may restrict growth opportunities.

Opportunities

  • Increasing demand for personalized medicine and targeted therapies provides opportunities for WAVE Life Sciences to develop tailored treatments.
  • Growing global healthcare market presents potential for expansion and market growth.
  • Emerging markets and untapped therapeutic areas offer possibilities for diversification and revenue expansion.

Threats

  • Intense competition within the biotechnology and pharmaceutical industries, with larger players having greater resources and market presence.
  • Stringent regulatory requirements and lengthy approval processes for new drugs may delay product commercialization.
  • Rapidly evolving technology and scientific advancements may render current products or research obsolete.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

WAVE Life Sciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

WAVE Life Sciences historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

WAVE Life Sciences shares outstanding

The number of shares was WAVE Life Sciences in 2023 — This indicates how many shares 106.097 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue WAVE Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates WAVE Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of WAVE Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating WAVE Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for WAVE Life Sciences.

WAVE Life Sciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.29 -0.47  (-64.22 %)2024 Q3
6/30/2024-0.21 -0.25  (-19.79 %)2024 Q2
3/31/2024-0.22 -0.24  (-11.06 %)2024 Q1
12/31/2023-0.23 -0.15  (34.47 %)2023 Q4
9/30/2023-0.18 0.07  (138.87 %)2023 Q3
6/30/2023-0.33 -0.2  (40.25 %)2023 Q2
3/31/2023-0.04 -0.27  (-568.32 %)2023 Q1
12/31/2022-0.41 -0.47  (-13.5 %)2022 Q4
9/30/2022-0.5 -0.42  (16.27 %)2022 Q3
6/30/2022-0.55 -0.62  (-12.85 %)2022 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the WAVE Life Sciences stock

Eulerpool World ESG Rating (EESG©)

71/ 100

🌱 Environment

36

👫 Social

99

🏛️ Governance

79

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees53
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

WAVE Life Sciences shareholders

%
Name
Stocks
Change
Date
11.93418 % RA Capital Management, LP18,202,009-16,1159/27/2024
10.99901 % GSK plc16,775,6912,791,9309/27/2024
5.02843 % Maverick Capital, Ltd.7,669,361-18,7186/30/2024
4.04180 % M28 Capital Management LP6,164,548-835,4526/30/2024
4.00138 % BlackRock Institutional Trust Company, N.A.6,102,901301,8136/30/2024
3.74053 % Shin Nippon Biomedical Laboratories Ltd5,705,06006/5/2024
3.51280 % Adage Capital Management, L.P.5,357,719156,3306/30/2024
3.49135 % 683 Capital Management LLC5,325,000-25,0006/30/2024
3.28152 % Emerald Advisers LLC5,004,976690,8089/30/2024
2.99387 % Invus Public Equities Advisors, LLC4,566,251514,8516/30/2024
1
2
3
4
5
...
10

WAVE Life Sciences Executives and Management Board

Dr. Paul Bolno

(49)
WAVE Life Sciences President, Chief Executive Officer, Director (since 2013)
Compensation 2.67 M

Dr. Christopher Francis

(45)
WAVE Life Sciences Senior Vice President - Corporate Development, Head - Emerging Areas
Compensation 1.68 M

Dr. Chandra Vargeese

(61)
WAVE Life Sciences Chief Technology Officer, Head - Platform Discovery Sciences
Compensation 1.23 M

Mr. Kyle Moran

(52)
WAVE Life Sciences Chief Financial Officer
Compensation 1.15 M

Dr. Gregory Verdine

(63)
WAVE Life Sciences Director
Compensation 628,058
1
2
3

WAVE Life Sciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Bio-Techne Stock
Bio-Techne
SupplierCustomer0,170,740,170,810,50-0,67
Takeda Pharmaceutical Stock
Takeda Pharmaceutical
SupplierCustomer-0,23-0,76-0,51-0,700,470,61
1

Most common questions regarding WAVE Life Sciences

What values and corporate philosophy does WAVE Life Sciences represent?

WAVE Life Sciences Ltd is committed to advancing precision medicine for patients with severe diseases. The company's corporate philosophy revolves around their innovative and proprietary platform technologies, designed to enable the development of highly specific, genetically targeted therapies. WAVE Life Sciences is dedicated to discovering and delivering transformative therapies to improve patients' lives, focusing on areas such as Huntington's disease, Duchenne muscular dystrophy, and other genetically defined diseases. With their scientific expertise and patient-centric approach, WAVE Life Sciences aims to revolutionize treatments and bring hope to those in need.

In which countries and regions is WAVE Life Sciences primarily present?

WAVE Life Sciences Ltd is primarily present in the United States and Singapore.

What significant milestones has the company WAVE Life Sciences achieved?

WAVE Life Sciences Ltd, a leading biotechnology company, has achieved several significant milestones. One of the notable accomplishments includes the successful development of its proprietary stereopure nucleic acid (NAC) platform. This innovative platform enables the design and production of highly specific, targeted therapies for various genetic diseases. Additionally, WAVE Life Sciences has made remarkable progress in advancing its pipeline of product candidates, especially in the areas of neurology, ophthalmology, and metabolism. The company's commitment to scientific excellence and dedication to improving patients' lives have been recognized through numerous partnerships and collaborations within the healthcare industry. WAVE Life Sciences Ltd continues to pave the way for transformative advancements in precision medicine.

What is the history and background of the company WAVE Life Sciences?

WAVE Life Sciences Ltd is a leading biotechnology company in the field of nucleic acid therapeutics. Established in 2012, the company focuses on developing transformational medicines for patients with genetic diseases. With a strong emphasis on precision medicine, WAVE Life Sciences utilizes its proprietary synthetic chemistry platform to design and optimize nucleic acid therapeutic candidates. The company has a diverse pipeline of potential treatments targeting various genetic disorders, including neurological, neuromuscular, and other rare diseases. WAVE Life Sciences continues to advance its innovative technologies and collaborate with partners to make significant advancements in the field of genetic medicine.

Who are the main competitors of WAVE Life Sciences in the market?

The main competitors of WAVE Life Sciences Ltd in the market include Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Regulus Therapeutics Inc. These companies operate in the same sector and focus on developing innovative solutions for genetic and neurological diseases. However, WAVE Life Sciences Ltd stands out by leveraging its proprietary chemistry platform to design and develop novel stereopure nucleic acid therapeutics. With its unique approach and dedication to advancing precision medicine, WAVE Life Sciences Ltd continues to differentiate itself from its competitors in the market.

In which industries is WAVE Life Sciences primarily active?

WAVE Life Sciences Ltd is primarily active in the healthcare and biotechnology industries.

What is the business model of WAVE Life Sciences?

The business model of WAVE Life Sciences Ltd revolves around utilizing proprietary nucleic acid platforms to develop and deliver transformative medicines for various diseases. WAVE Life Sciences focuses on designing and developing stereopure nucleic acid therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA). These therapeutics are designed to address the underlying cause of genetic diseases, neurological disorders, and other conditions at the genetic level. With a strong emphasis on genetic precision, WAVE Life Sciences aims to create targeted and personalized treatments that provide patients with better healthcare outcomes.

What is the P/E ratio of WAVE Life Sciences 2024?

The WAVE Life Sciences P/E ratio is -9.22.

What is the P/S ratio of WAVE Life Sciences 2024?

The WAVE Life Sciences P/S ratio is 27.9.

What is the Quality Investing of WAVE Life Sciences?

The Quality Investing for WAVE Life Sciences is 4/10.

What is the revenue of WAVE Life Sciences 2024?

The expected WAVE Life Sciences revenue is 58.55 M USD.

How high is the profit of WAVE Life Sciences 2024?

The expected WAVE Life Sciences profit is -177.15 M USD.

What is the business model of WAVE Life Sciences

WAVE Life Sciences Ltd is a biopharmaceutical company based in Singapore that focuses on the discovery, development, and commercialization of therapies for the treatment of genetically related diseases. The company utilizes its own technologies to manufacture oligonucleotide-based therapeutics that aim to correct mutations in RNA or DNA sequences. One of WAVE Life Sciences' key areas is the development of therapies for the treatment of Huntington's, an autosomal dominant neurodegenerative disease. The company is working on developing a new generation of oligonucleotide-based drugs that specifically target the correction of the mutated huntingtin protein sequence. These therapies aim to slow down or even stop the progression of the disease. WAVE Life Sciences also develops therapies for the treatment of neuromuscular diseases, including Duchenne and Becker muscular dystrophy. The company has formed partnerships with leading research institutions and companies to ensure that its therapeutics are thoroughly tested and validated in various stages of development and areas of indication. The company presents an opportunity to enter the growing market for RNA-based therapeutics, which holds great promise for the development of novel treatment options for many diseases. WAVE Life Sciences has a unique portfolio of therapeutic approaches that target the correction of mutations in specific genes, positioning the company uniquely to deliver significant therapeutic benefits. WAVE Life Sciences offers an innovative business model built on scientific excellence and strategic partnerships to advance the development of life-changing therapies with high potential benefit for patients. The company's discoveries and technologies are protected by a strong intellectual property position, and its research efforts are continuously expanding to increase the diversity of genetic diseases being treated. Overall, WAVE Life Sciences is well-positioned for success in the growing RNA-based therapeutics market through its leadership in innovation and partnerships, its RNA-based technology portfolio, and its strong intellectual property position, offering significant growth potential to its shareholders.

What is the WAVE Life Sciences dividend?

WAVE Life Sciences pays a dividend of 0 USD distributed over payouts per year.

How often does WAVE Life Sciences pay dividends?

The dividend cannot currently be calculated for WAVE Life Sciences or the company does not pay out a dividend.

What is the WAVE Life Sciences ISIN?

The ISIN of WAVE Life Sciences is SG9999014716.

What is the WAVE Life Sciences WKN?

The WKN of WAVE Life Sciences is A1436W.

What is the WAVE Life Sciences ticker?

The ticker of WAVE Life Sciences is WVE.

How much dividend does WAVE Life Sciences pay?

Over the past 12 months, WAVE Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, WAVE Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of WAVE Life Sciences?

The current dividend yield of WAVE Life Sciences is .

When does WAVE Life Sciences pay dividends?

WAVE Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of WAVE Life Sciences?

WAVE Life Sciences paid dividends every year for the past 0 years.

What is the dividend of WAVE Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is WAVE Life Sciences located?

WAVE Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von WAVE Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of WAVE Life Sciences from 12/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/2/2024.

When did WAVE Life Sciences pay the last dividend?

The last dividend was paid out on 12/2/2024.

What was the dividend of WAVE Life Sciences in the year 2023?

In the year 2023, WAVE Life Sciences distributed 0 USD as dividends.

In which currency does WAVE Life Sciences pay out the dividend?

The dividends of WAVE Life Sciences are distributed in USD.

All fundamentals about WAVE Life Sciences

Our stock analysis for WAVE Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of WAVE Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.